Analyst Reni Benjamin of JMP Securities maintained a Buy rating on Bicycle Therapeutics (BCYC – Research Report), retaining the price target of $26.00. Discover outperforming stocks and invest ...
(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin ...
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback